Table of Contents
Epilepsy Treatment Market Overview
Epilepsy treatment devices like Vagus Nerve Stimulation (VNS), Responsive Neurostimulation (RNS), and Deep Brain Stimulation (DBS) go beyond medications to manage seizures effectively.
VNS uses an implanted device to stimulate the vagus nerve and potentially reduce seizure severity. RNS detects abnormal brain activity and delivers targeted electrical stimulation to prevent seizures.
DBS implants electrodes in specific brain areas to regulate electrical activity. Wearable seizure detection devices monitor vital signs, alerting caregivers to seizures in real-time.
These innovations provide options for people with drug-resistant epilepsy or those unable to undergo surgery. Improving seizure control and quality of life with precise, responsive therapies.
Market Drivers
Technological advancements in devices such as Vagus Nerve Stimulation (VNS), and Responsive Neurostimulation (RNS). Wearable seizure detectors are expanding epilepsy treatment options beyond drugs, driving global market growth.
The rising prevalence of epilepsy, influenced by aging populations and better diagnosis, increases the demand for effective treatments.
Improved awareness and healthcare infrastructure enable earlier diagnosis and treatment, fostering market expansion. Innovations in personalized patient care are enhancing therapy development.
Substantial investments in research and development by pharmaceutical and device manufacturers and favorable government policies are also boosting market growth.
Market Size
According to Epileptics Statistics, the Epilepsy Treatment Market is expected to grow to around USD 13.4 billion by 2032 from USD 6.5 billion in 2022. Expanding at a 7.7% CAGR during the forecast period from 2023 to 2032.
List of Major Companies
These are the top ten companies operating in the mRNA Market:
Abbott
Company Overview
| Establishment Year | 1888 |
| Headquarter | Green Oaks, Illinois, U.S. |
| Key Management | Robert B. Ford (Chairman & CEO) |
| Revenue (US$ Bn) | $ 40.1 Billion (2023) |
| Headcount | ~ 114,000 (2023) |
| Website | http://abbott.com/ |
About Abbott Laboratories
Abbott Laboratories has been actively involved in the epilepsy treatment devices sector through its Neuromodulation segment, which includes devices for managing neurological conditions.
Recently, Abbott achieved FDA approval for its Liberta RC Deep Brain Stimulation (DBS) system. Which is designed to help manage movement disorders and holds potential applications for epilepsy treatment.
Additionally, Abbott’s broader medical device portfolio has shown robust growth, with a 14.2% increase in sales in Q1 2024.
Driven by innovations such as the Esprit BTK dissolving stent for chronic limb-threatening ischemia and the TriClip device for tricuspid valve repair.
These advancements reflect Abbott’s commitment to developing cutting-edge medical technologies that enhance patient outcomes across various therapeutic areas.
Geographical Presence
Abbott Laboratories, headquartered in the US, has a substantial global presence spanning North America, Europe, Asia-Pacific, Latin America, and the Middle East/Africa.
In North America, it operates facilities in Illinois, Texas, and California. In Europe, Abbott has operations in Germany, Ireland, the UK, France, Italy, and Spain.
Across Asia-Pacific, it has hubs in China, India, Japan, South Korea, Australia, and Singapore. In Latin America, Abbott is present in Brazil, Mexico, Argentina, Chile, and Colombia.
It also operates in key Middle Eastern and African markets, including South Africa, Saudi Arabia, UAE, Egypt, and Nigeria.
Abbott’s extensive global network supports its mission to deliver healthcare solutions globally through localized manufacturing and robust distribution channels.
Recent Developments
- In June 2024, Abbott Laboratories collaborated with the National Association of Community Health Centers to enhance access to healthy food and support overall health via its Innovation Incubator program.
- In April 2024, Abbott’s FDA approval of the Esprit™ BTK System represented a major advancement in treating chronic limb-threatening ischemia (CLTI) below the knee, offering a breakthrough for patients with this condition.
Merck
Company Overview
| Establishment Year | 1891 |
| Headquarter | Rahway, New Jersey, U.S. |
| Key Management | Robert M. Davis (Chairman, President and CEO) |
| Revenue (US$ Bn) | $ 60.1 B (2023) |
| Headcount | ~ 72,000 (2023) |
| Website | http://merck.com/ |
About Merck
Merck & Co., Inc., known as MSD outside the U.S. and Canada, traditionally focuses on pharmaceuticals and biotechnology rather than epilepsy treatment devices.
Despite this, the company has made strides in benefiting the neurological field, including epilepsy. Recently acquiring EyeBio, a biotech specializing in retinal diseases, showcases Merck’s commitment to broadening its therapeutic offerings through strategic acquisitions.
Additionally, Merck continues to innovate with products like WINREVAIR for pulmonary arterial hypertension and KEYTRUDA for diverse cancers.
Highlighting its dedication to tackling complex health challenges through advanced research and acquisitions.
Geographical Presence
Merck & Co., Inc. has a strong presence across North America, Europe, Asia-Pacific, Latin America, and the Middle East/Africa.
In the U.S., it is headquartered in Kenilworth, New Jersey, with numerous facilities nationwide. In Europe, offices and research centers are strategically located in Germany, France, the UK, and Italy to serve diverse healthcare needs.
In Asia-Pacific, Merck & Co. focuses on markets like China, Japan, and India while also expanding in Latin America.
Including Brazil Mexico, and the Middle East/Africa through key market operations. This extensive global network supports local innovation while maintaining a unified global strategy from its central headquarters.
Recent Developments
- In May 2024, Merck, through a subsidiary, entered a definitive agreement to acquire Eyebiotech Limited, a privately held biotech company focused on ophthalmology.
- In October 2022, Merck reported promising results from the Phase 3 STELLAR trial, showing that sotatercept, an investigational fusion protein (ActRIIA-Fc), demonstrated positive safety and efficacy outcomes as an additional therapy for pulmonary arterial hypertension (PAH).
GSK
Company Overview
| Establishment Year | 2000 |
| Headquarter | London, England, UK |
| Key Management | Emma Walmsley (CEO) |
| Revenue (US$ Bn) | $ 37.7 Billion (2022) |
| Headcount | ~ 70,000 (2024) |
| Website | https://www.gsk.com/ |
About GSK
GSK plc focuses mainly on advancing pharmaceuticals rather than epilepsy treatment devices. Working with Valeant Pharmaceuticals, GSK secured European approval for Trobalt (retigabine) as an adjunctive therapy for adults with partial-onset seizures.
Recently, GSK has expanded its treatment options and sustainability efforts. Early in 2024, the company reported strong financial performance and progress in its pipeline, including successful phase III trials for Blenrep in treating multiple myeloma.
GSK is also moving towards phase III trials for a low-carbon version of its Ventolin inhaler, aiming to reduce its environmental impact by 2025.
Furthermore, the FDA accepted GSK’s application to broaden the use of Jemperli (dostarlimab) for adults with primary advanced or recurrent endometrial cancer, underscoring its commitment to oncology innovation.
These developments underscore GSK’s dedication to advancing healthcare solutions and supporting environmental sustainability.
Geographical Presence
GSK plc has a strong global presence spanning North America, Europe, Asia-Pacific, and emerging markets in Latin America, Africa, and the Middle East.
In North America, it operates from key centers such as the U.S., focusing on research, manufacturing, and commercial activities.
The company’s global headquarters in the UK supports extensive research and regulatory efforts across Europe.
In the Asia-Pacific region, GSK utilizes markets like China and India for manufacturing and clinical trials. Emerging markets offer growth opportunities, with GSK investing in local infrastructure and healthcare partnerships.
This global footprint allows GSK to innovate and deliver healthcare solutions tailored to diverse regional needs while ensuring operational integration and sustainability.
Recent Development
- In June 2024, GSK and Ochre Bio entered into a partnership to develop therapeutics for liver diseases.
- In November 2023, GSK announced plans to initiate Phase III trials for a low-carbon version of its metered dose inhaler, Ventolin (salbutamol), utilizing an advanced propellant.
Thermo-Fisher
Company Overview
| Establishment Year | 1958 |
| Headquarter | Waltham, Massachusetts, U.S. |
| Key Management | Marc N. Casper (CEO) |
| Revenue (US$ Bn) | $ 42.8 Billion (2023) |
| Headcount | ~ 122,000 (2023) |
| Website | http://www.thermofisher.com/ |
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is actively advancing epilepsy research through cutting-edge neurobiology studies, particularly using cryo-electron microscopy to examine neuronal ion channels like the Kv3.1a potassium channel, crucial in hereditary epileptic disorders.
Their detailed structural analyses are pivotal for targeted epilepsy treatments. Recently, Thermo Fisher has bolstered its capabilities with strategic acquisitions and product innovations.
They’ve expanded clinical research labs in Kentucky and Wisconsin to support broader trials and launched the Thermo Scientific™ KingFisher™ PlasmidPro Maxi Processor, enhancing therapy discovery and development speed.
These initiatives underscore Thermo Fisher’s dedication to pioneering healthcare solutions and advancing scientific research.
Geographical Presence
Thermo Fisher Scientific Inc., based in Waltham, Massachusetts, USA, has a strong global presence spanning North America, Europe, Asia-Pacific, Latin America, and the Middle East/Africa.
It operates extensive manufacturing and research facilities in the US, Canada, Germany, the UK, France, Italy, China, Japan, India, Australia, Brazil, Mexico, South Africa, and the UAE.
This strategic footprint supports the company’s leadership in providing scientific instruments and healthcare solutions worldwide.
Recent Development
- In June 2024, Thermo Fisher Scientific inaugurated a new ultra-cold GMP facility for clinical and commercial purposes in Bleiswijk, the Netherlands.
- In June 2024, Thermo Fisher Scientific launched the Thermo Scientific Heracell VIOS 250i AxD CO2 Incubators.
Bausch-Health
Company Overview
| Establishment Year | 1959 |
| Headquarter | Laval, Quebec, Canada |
| Key Management | Thomas J. Appio (CEO) |
| Revenue (US$ Bn) | $ 8.8 B (2022) |
| Headcount | ~ 20,270 (2022) |
| Website | http://bauschhealth.com/ |
About Bausch Health
Bristol Bausch Health has been actively engaged in the epilepsy sector through its development and distribution of epilepsy medications.
The company is part of the growing global epilepsy drugs market, which is expected to expand significantly by 2030 due to increased awareness and advancements in treatment options.
Recently, Bausch Health has focused on strengthening its financial standing, reporting a significant revenue increase in the first quarter of 2024.
Strategic initiatives include product development and addressing market needs for effective epilepsy treatments.
Bausch Health has also been involved in litigation to protect its drug patents, which impacts its overall market strategy.
Geographical Presence
Bausch Health Companies Inc., based in Laval, Quebec, Canada, maintains a strong global presence across North America, Europe, Asia-Pacific, and Latin America.
It serves prominently in the United States and Canada, leads in key European markets, expands in Asia-Pacific’s emerging markets, and enhances access in Latin America and other regions.
This extensive reach enables Bausch Health to meet diverse healthcare needs worldwide, affirming its stature as a leading global pharmaceutical company.
Recent Developments
- In April 2024, Bausch Health Canada launched PrARAZLOTM, a treatment for acne vulgaris.
- In January 2024, Bausch Health launched CABTREO (clindamycin, adapalene, benzoyl peroxide) Topical Gel, 1.2%/0.15%/3.1% in the US.
Teva
Company Overview
| Establishment Year | 1901 |
| Headquarter | Tel Aviv, Israel |
| Key Management | Richard Francis (President and CEO) |
| Revenue (US$ Bn) | $ 15.8 Billion (2023) |
| Headcount | ~ 35,000 (2023) |
| Website | http://www.tevapharm.com/ |
About Teva Pharmaceuticals
Teva Pharmaceuticals has actively expanded its presence in epilepsy treatment, focusing on enhancing its portfolio with new drugs and strategic partnerships.
A notable addition is AUSTEDO XR, an extended-release medication for Huntington’s disease and tardive dyskinesia, offering improved patient outcomes with once-daily dosing.
Teva also collaborates with Medincell on TEV- ‘749, a long-acting injectable for schizophrenia, showing promising efficacy in phase 3 trials.
Financially, Teva has seen steady growth, driven by increased revenues and operational efficiencies. These initiatives underscore Teva’s dedication to advancing therapies and enhancing life quality for epilepsy and neurological disorder patients.
Geographical Presence
Teva Pharmaceuticals has a strong global presence spanning North America (with a focus on the U.S. and Canada), Europe (including Germany, the UK, Spain, and Hungary), Asia Pacific (covering Japan, Australia, South Korea, and China), Latin America (with markets in Brazil and Mexico), and the Middle East/Africa.
This broad reach supports Teva’s mission to offer affordable healthcare solutions globally, emphasizing both generic and specialty pharmaceuticals.
Recent Developments
- In May 2024, Teva Pharmaceuticals announced FDA approval for AUSTEDO XR, now available in four new tablet strengths (30 mg, 36 mg, 42 mg, and 48 mg). This extended-release formulation is indicated for adults with tardive dyskinesia (TD) and Huntington’s disease chorea, offering a convenient once-daily treatment option.
- In May 2024, Teva Pharmaceuticals and Medincell reported results from the efficacy phase of the Phase 3 SOLARIS trial, which assessed TEV- ‘749, a subcutaneous extended-release olanzapine injection, in adults with schizophrenia versus placebo.
Roche
Company Overview
| Establishment Year | 1896 |
| Headquarter | Basel, Switzerland |
| Key Management | Thomas Schinecker (CEO) |
| Revenue (US$ Bn) | $ 65.4 Billion (2022) |
| Headcount | ~ 122,000 (2022) |
| Website | http://www.roche.com/ |
About Roche
Roche has made significant strides in the epilepsy treatment sector through strategic acquisitions, partnerships, and innovative product development.
Recently, Roche’s subsidiary, Spark Therapeutics, secured a licensing deal worth up to $328.5 million with CombiGene for a promising gene therapy targeting drug-resistant focal epilepsy.
This therapy aims to address the needs of approximately 47,000 patients who do not respond to conventional treatments.
Additionally, Roche continues to invest heavily in neurology research, focusing on developing precise treatments tailored to individual patient needs by integrating advanced diagnostics and data science.
The company’s strategy emphasizes partnerships and external collaborations to drive innovation and improve patient outcomes in epilepsy management.
Geographical Presence
Roche Holding AG, based in Basel, Switzerland, maintains a strong global presence with strategic hubs across North America (including New York, San Francisco, and Indianapolis), Europe (Germany, France, the UK, Italy, and Switzerland), Asia-Pacific (Japan, China, Australia, and Singapore), Latin America (Brazil and Mexico), and the Middle East/Africa (South Africa and the UAE).
This expansive presence enables Roche to lead in pharmaceuticals and diagnostics worldwide, adapting strategies to meet diverse regional healthcare requirements.
Recent Developments
- In July 2024, Roche obtained FDA approval for Vabysmo PFS to treat retinal conditions leading to potential blindness.
- In June 2024, Roche Digital Pathology Dx received approval from the US Food and Drug Administration.
Pfizer
Company Overview
| Establishment Year | 1849 |
| Headquarter | New York City, U.S. |
| Key Management | Albert Bourla (CEO) |
| Revenue (US$ Bn) | $ 58.5 Billion (2023) |
| Headcount | ~ 88,000 (2023) |
| Website | http://pfizer.com/ |
About Pfizer
Pfizer has actively enhanced its efforts in treating epilepsy, collaborating with the Epilepsy Foundation and Intellimedix to develop a personalized drug discovery platform.
This initiative targets genetic forms like Dravet Syndrome, aiming to create tailored therapies for drug-resistant epilepsy patients.
Pfizer also achieved promising results in a Phase 3 trial of LYRICA® Oral Solution CV for pediatric epilepsy, showing a notable decrease in seizure frequency.
These advancements highlight Pfizer’s dedication to expanding treatment choices for epilepsy patients, especially those facing complex conditions.
Geographical Presence
Pfizer Inc., based in New York City, maintains a robust global presence spanning North America, Europe (including the UK, Germany, and France), Asia-Pacific (Japan, China, India), Latin America (Brazil, Mexico, Argentina), and the Middle East/Africa (South Africa, Egypt).
The company operates extensive facilities for manufacturing, research, and administration, focusing on delivering innovative healthcare solutions tailored to diverse regional markets and regulatory environments worldwide.
Recent Development
- In June 2024, Pfizer obtained approval in Japan to market the combination antibiotic Zabicefta Combination Intravenous Infusion, which includes a beta-lactamase inhibitor.
- In June 2024, Pfizer partnered with Relay Therapeutics, Inc. to study atirmociclib alongside RLY-2608 and fulvestrant in patients with PI3Kα-mutated, HR+, and HER2-mastatic breast cancer.
Qiagen
Company Overview
| Establishment Year | 1984 |
| Headquarter | Venlo, Netherlands |
| Key Management | Thierry Bernard (CEO) |
| Revenue (US$ Bn) | $ 1.9 Billion (2023) |
| Headcount | ~ 5,967 (2023) |
| Website | http://qiagen.com/ |
About Qiagen
Qiagen, a leading provider of molecular testing solutions, is making significant strides in the epilepsy treatment sector.
The company has recently focused on enhancing its portfolio with innovative products and strategic initiatives.
In early 2024, Qiagen announced a $300 million share repurchase program designed to optimize shareholder value and support its growth trajectory.
This move follows their strategy to invest in profitable growth and explore targeted mergers and acquisitions.
Qiagen’s technologies, which include advanced DNA, RNA, and protein isolation methods, are pivotal in developing diagnostic tools and treatments for neurological conditions like epilepsy.
Their commitment to advancing molecular insights and bioinformatics is contributing to improved clinical outcomes and personalized medicine in epilepsy care.
Geographical Presence
Qiagen, a leading player in life sciences and molecular diagnostics, maintains a strong global presence across North America, Europe, Asia-Pacific, Latin America, and the Middle East/Africa regions.
Headquartered in Germany, Qiagen operates extensive facilities and offices strategically positioned to serve key markets.
In North America, it supports a broad customer base in molecular diagnostics and pharmaceutical research.
Europe serves as a hub for R&D, focusing on molecular testing technologies. In the Asia-Pacific region, Qiagen targets emerging markets like China and Japan.
Latin America and the Middle East/Africa regions also benefit from Qiagen’s expanding footprint, enhancing access to its diagnostic solutions and reinforcing its global leadership in the industry.
Recent Developments
- In June 2024, Qiagen introduced its new digital PCR Custom Assay Design Tool for copy number variation analysis.
- In June 2024, Qiagen unveiled the QIAstat-Dx Gastrointestinal Panel 2 in the US.
GE-Healthcare
Company Overview
| Establishment Year | 1994 |
| Headquarter | Chicago, Illinois, U.S. |
| Key Management | Peter Arduini (CEO) |
| Revenue (US$ Bn) | $ 19.5 Billion (2023) |
| Headcount | ~ 51,000 (2023) |
| Website | http://gehealthcare.com/ |
Business Description
GE Healthcare is actively advancing epilepsy treatment through innovative medical technologies. Collaborating with Elekta and MIM Software, GE aims to enhance radiation oncology treatment planning, benefiting conditions like epilepsy.
Their focus includes integrating advanced imaging tools for early epilepsy detection. Additionally, a recent partnership with Novo Nordisk explores non-invasive treatment using peripheral-focused ultrasound technology, originally for metabolic diseases but potentially impactful in epilepsy care.
These efforts underscore GE Healthcare’s dedication to enhancing patient outcomes through technological innovation and strategic collaborations.
Geographical Presence
GE Healthcare maintains a robust global presence across North America, Europe, Asia-Pacific, Latin America, the Middle East, Africa, and Oceania.
In North America, it serves the United States with advanced diagnostic imaging systems and healthcare IT solutions.
Europe hosts key operations in the UK, Germany, France, and Italy, offering a wide range of medical technologies.
In Asia-Pacific, GE Healthcare addresses healthcare needs in China, India, and Japan with diagnostic imaging and digital healthcare solutions.
Latin America, including Brazil and Mexico, benefits from its medical equipment and services. The company also supports healthcare infrastructure in the Middle East, including the UAE, and across Africa.
In Oceania, it provides diagnostic imaging and healthcare IT to Australia and New Zealand, enhancing global healthcare delivery.
Recent Developments
- In April 2024, GE Healthcare announced a collaboration between Elekta and MIM Software Inc., a leading provider of medical imaging management and AI solutions, aimed at integrating top-tier technologies for advanced radiation therapy treatment planning.
- In October 2023, GE Healthcare and Novo Nordisk collaborated to develop peripheral-focused ultrasound (PFUS), an innovative technology for regulating metabolic function using ultrasound. This advancement holds the potential for treating chronic diseases such as type 2 diabetes and obesity.
